Sleep Disorders
Methodology & AI Transparency ⓘ
Sleep Disorders Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is sleep? While you are sleeping your brain and body functions are still active.
- 2 Real-world patient consensus: Diagnostic registry G47.419: Sleep Disorders is managed within Sleep Disorders.
- 3 Typical cash cost range: Workup highlights for Sleep Disorders (G47.419): airway pressure or in Sleep Disorders (G47.419: orexin-targeted therapy evaluation).
- 4 Top reported side effects / signs: Objective lab/clinical target for Sleep Disorders: Insomnia Severity Index in Sleep Disorders (G47.419: (ISI)) (< 7 (G47.419)) and Nocturnal Oxygen Saturation in Sleep Disorders (G47.419: (SpO2)).
Ask our AI Specialists anything about Sleep Disorders
What Is Sleep Disorders?
What is sleep? While you are sleeping your brain and body functions are still active. Sleep is a natural process that helps your body restore energy, supports learning and memory, and keeps you healthy. It's not just the number of hours of sleep you get that matters. The quality of your sleep is also important. During the night, your brain cycles through different stages of non-rapid eye movement (non-REM) sleep and rapid eye movement (REM) sleep. If your sleep is often interrupted, you may not get enough time in certain stages of sleep. Poor-quality sleep does more than make you feel tired. It can affect your physical and mental health, thinking, and daily functioning.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in sleep disorders, Sleep Disorders (G47.419) involves fragmented slow-wave/REM sleep in Sleep Disorders (G47.419: architecture). Cross-referenced with NIH MeSH (Sleep Wake Disorders), progression correlates with shifts in Insomnia Severity Index in Sleep Disorders (G47.419: (ISI)) (< 7 (G47.419)).
Common Symptoms & Clinical Signs
- • Insomnia , which is trouble falling asleep or staying asleep
- • Sleep-related breathing disorders such as sleep apnea , a condition in which you stop breathing for 10 seconds or more during sleep
- • Presentation of Sleep Disorders (G47.419): unrefreshing morning waking in Sleep Disorders (G47.419: despite adequate hours)
- • Secondary Sleep Disorders clinical sign: loud habitual snoring, in Sleep Disorders (G47.419: witnessed breathing pauses,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Sleep Disorders Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | G47.419 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Insomnia Severity Index in Sleep Disorders (G47.419: (ISI)) | < 7 (G47.419) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Sleep Disorders (G47.419: (SpO2)) | >= 94% nadir > 90% (G47.419) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Ferritin (Restless in Sleep Disorders (G47.419: Legs)) | > 75 ng/mL (G47.419) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sleep Disorders
Treatment selection for Sleep Disorders depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sleep Disorders)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Exogenous melatonin on: What a 284-Participant Study Found Since 15 of the 17 studies enrolled healthy subjects or people with no relevant medical condition other than trouble sleeping, the analysis was also done including only these 15 studies. Sleep medicine reviews • 2005-02-15 • Meta-Analysis | N = 284 | 97/100 | PMID 15649737 ↗ |
| New Insights on Effect of fezolinetant on sleep disturbance and impairment during treatment of: What a 1,022-Participant Study Found Fezolinetant had a beneficial effect on four measures of sleep disturbance and impairment following treatment for VMS. Maturitas • 2024-08-15 • Phase III Randomized Trial | N = 1,022 | 96/100 | PMID 38749864 ↗ |
| New Insights on A network meta-analysis of the long- and short-term efficacy of sleep medicines: What a 25,923-Participant Study Found ORAs can be widely used in adults and the older adults, and both short-term and long-term use are effective for primary trouble sleeping. Neuroscience and biobehavioral reviews • 2021-12-15 • Meta-Analysis | N = 25,923 | 94/100 | PMID 34560134 ↗ |
| New Insights on Association between obstructive sleep apnea and male serum: What a 1,823-Participant Study Found Obstructive sleep apnea is inversely associated with male serum testosterone levels, independent of body mass index and age. Andrology • 2022-02-15 • Meta-Analysis | N = 1,823 | 94/100 | PMID 34536053 ↗ |
| New Insights on Association between obstructive sleep apnea and metabolic: What a 2,053-Participant Study Found Ten studies were included in the analysis which included 2053 patients. Clinical and investigative medicine. Medecine clinique et experimentale • 2016-10-14 • Meta-Analysis | N = 2,053 | 94/100 | PMID 27805899 ↗ |
Sleep Disorders Patient Community & “People Like Me” Threads
Filter Sleep Disorders community threads and patient logs by age, biological sex, dosage, and treatment duration.